Randomized Controlled Trial of Moxifloxacin Compared With Piperacillin???Tazobactam and Amoxicillin???Clavulanate for the Treatment of Complicated Intra-abdominal Infections
- 1 August 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 244 (2) , 204-211
- https://doi.org/10.1097/01.sla.0000230024.84190.a8
Abstract
To compare the safety and efficacy of sequential intravenous (IV) to oral (PO) moxifloxacin treatment against a standard antimicrobial regimen of IV piperacillin-tazobactam followed by PO amoxicillin-clavulanate for the treatment of adults with complicated intra-abdominal infection (cIAI). cIAIs are commonly due to mixed aerobic and anaerobic bacteria and require both source control and broad-spectrum antibiotic therapy. A prospective, double-blind, randomized, phase III comparative trial. Patients with cIAI were stratified by disease severity (APACHE II score) and randomized to either IV/PO moxifloxacin (400 mg q24 hours) or comparator (IV piperacillin-tazobactam [3.0/0.375 g q6 hours] +/- PO amoxicillin-clavulanate [800 mg/114 mg q12 hours]), each for 5 to 14 days. The primary efficacy variable was clinical cure rate at the test-of-cure visit (days 25-50). Bacteriologic outcomes were also determined. : Of 656 intent-to-treat patients, 379 (58%) were valid to assess efficacy (183 moxifloxacin, 196 comparator). Demographic and baseline medical characteristics were similar between the 2 groups. Clinical cure rates at test-of-cure were 80% (146 of 183) for moxifloxacin versus 78% (153 of 196) for comparator (95% confidence interval, -7.4%, 9.3%). The clinical cure rate at test-of-cure for hospital-acquired cIAI was higher with moxifloxacin (82%, 22 of 27) versus comparator (55%, 17 of 31; P = 0.05); rates were similar for community-acquired infections (80% [124 of 156] versus 82% [136 of 165], respectively). Bacterial eradication rates were 78% (117 of 150) with moxifloxacin versus 77% (126 of 163) in the comparator group (95% confidence interval, -9.9%, 8.7%). Once daily IV/PO moxifloxacin monotherapy was as least as effective as standard IV piperacillin-tazobactam/PO amoxicillin-clavulanate dosed multiple times daily for the treatment of cIAIs.Keywords
This publication has 16 references indexed in Scilit:
- Moxifloxacin penetration into human gastrointestinal tissuesJournal of Antimicrobial Chemotherapy, 2004
- In Vitro Activities of Moxifloxacin against 900 Aerobic and Anaerobic Surgical Isolates from Patients with Intra-Abdominal and Diabetic Foot InfectionsAntimicrobial Agents and Chemotherapy, 2004
- Guidelines for the Selection of Anti-infective Agents for Complicated Intra-abdominal InfectionsClinical Infectious Diseases, 2003
- The Surgical Infection Society Guidelines on Antimicrobial Therapy for Intra-Abdominal Infections: Evidence for the RecommendationsSurgical Infections, 2002
- Pharmacokinetics of moxifloxacin, a novel 8‐methoxy‐quinolone, in patients with renal dysfunctionBritish Journal of Clinical Pharmacology, 2002
- Antimicrobial therapy for intraabdominal infectionThe American Journal of Surgery, 1996
- Results of a Randomized Trial Comparing Sequential Intravenous/Oral Treatment with Ciprofloxacin Plus Metronidazole to Imipenem/Cilastatin for Intra-Abdominal InfectionsAnnals of Surgery, 1996
- Antibiotic Treatment for Surgical PeritonitisAnnals of Surgery, 1991
- Results of a Multicenter Trial Comparing Imipenem/Cilastatin to Tobramycin/Clindamycin for Intra-abdominal InfectionsAnnals of Surgery, 1990
- Antibiotic management of surgically treated gangrenous or perforated appendicitis: Comparison of gentamicin and clindamycin versus cefamandole versus cefoperazoneThe American Journal of Surgery, 1982